Real-world effectiveness of b/tsDMARD switching in low-inflammatory difficult-to-treat rheumatoid arthritis: insights from the FIRST registry

RMD Open 2026 Open access

Read full text
Authors: Hidenori Sakai, Koshiro Sonomoto, Shingo Nakayamada, Masanobu Ueno, Atsushi Nagayasu, Takafumi Aritomi, Hiroaki Tanaka, Satoshi Kubo, Ippei Miyagawa, Yasuyuki Todoroki, Yurie Satoh-Kanda, Yuya Fujita
+2 more Ryuichiro Kanda, Yoshiya Tanaka
DOI: 10.1136/rmdopen-2025-006513
Cited by: 2
References: 37

Abstract

OBJECTIVES: To assess the effectiveness of switching biological or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in patients with low-inflammatory difficult-to-treat rheumatoid arthritis (D2T RA). METHODS: Using the multicentre FIRST registry, we identified D2T RA between August 2013 and March 2024. Low-inflammatory D2T RA was defined as a swollen 28-joint count ≤1 and C-reactive protein

Fields of Study & Subjects

Rheumatoid Arthritis Research and Therapies Biosimilars and Bioanalytical Methods Autoimmune and Inflammatory Disorders Research

Publication details

Journal / source
RMD Open
Publisher
BMJ
Volume
12
Issue
1
Pages
e006513–e006513
Publication date
1 January 2026
Language
EN